MarketPulse

FDA approval delay

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Crashes 49% After FDA Rejects Gene Therapy Data; Class Action Launched

uniQure faces securities fraud lawsuit after FDA rejection of AMT-130 data triggers 49% stock plunge from $67.69 to $34.29 on November 3, 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Plummets 49% After FDA Rejection; Securities Fraud Suit Filed

uniQure's stock plummeted 49% after FDA rejected its AMT-130 drug candidate; securities fraud lawsuit filed for alleged failure to disclose approval risks during September-October 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure, Gartner Face Securities Fraud Suits Over Material Disclosure Failures

Law firm files class actions against uniQure, Gartner, and Trip.com for alleged failure to disclose material information. Stock declines range from 19% to 49%.
QUREITTCOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Crashes 49% After FDA Rejects Gene Therapy Data

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Drops 49% Following FDA Rejection of AMT-130 Accelerated Approval

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.
QUREsecurities fraudclass action lawsuit